PCM
KYMR icon

Peregrine Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Peregrine Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.24M Buy
+45,671
New +$3.92M 0.17% 189

Other funds holding KYMR

MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
KMWM
Keudell/Morrison Wealth Management Salem, Oregon $529M AUM
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM
JWA
JFS Wealth Advisors Hermitage, Pennsylvania $2.01B AUM 21.74% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return

Peregrine Capital Management's KYMR Position: Q2 2026 in Review

Peregrine Capital Management opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 45,671 shares worth $5.24M. The stake represents 0.17% of the portfolio and ranks #189 among its holdings.

12 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Peregrine Capital Management held 45,671 shares of Kymera Therapeutics worth $5.24M as of Q2 2026.
  • Kymera Therapeutics was a new Peregrine Capital Management position in Q2 2026.
  • Kymera Therapeutics made up 0.17% of Peregrine Capital Management's portfolio in Q2 2026, its #189 holding.
  • 12 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Peregrine Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.